These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25119062)

  • 1. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.
    Reck M; Heigener D; Reinmuth N
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):579-90. PubMed ID: 25119062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
    Dhillon S
    Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
    Popat S; Mellemgaard A; Fahrbach K; Martin A; Rizzo M; Kaiser R; Griebsch I; Reck M
    Future Oncol; 2015; 11(3):409-20. PubMed ID: 25478720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
    Syrios J; Nintos G; Georgoulias V
    Expert Rev Anticancer Ther; 2015; 15(8):875-84. PubMed ID: 26204906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
    Novello S; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Barrueco J; Gaschler-Markefski B; Griebsch I; Palmer M; Reck M;
    Eur J Cancer; 2015 Feb; 51(3):317-26. PubMed ID: 25534294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
    Reck M; Mellemgaard A; von Pawel J; Gottfried M; Bondarenko I; Cheng Y; Zarogoulidis K; Luft A; Bennouna J; Barrueco J; Aboshady H; Hocke J; Kaiser R; Douillard JY;
    Lung Cancer; 2015 Nov; 90(2):267-73. PubMed ID: 26415992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
    Espinosa Bosch M; Asensi Diez R; García Agudo S; Clopes Estela A
    Farm Hosp; 2016 Jun; 40(4):316-27. PubMed ID: 27571499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
    Noonan S; Man Wong K; Jimeno A
    Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
    Okamoto I; Miyazaki M; Takeda M; Terashima M; Azuma K; Hayashi H; Kaneda H; Kurata T; Tsurutani J; Seto T; Hirai F; Konishi K; Sarashina A; Yagi N; Kaiser R; Nakagawa K
    J Thorac Oncol; 2015 Feb; 10(2):346-52. PubMed ID: 25299232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib in non-small cell lung cancer: from preclinical to approval.
    Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
    Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
    Gottfried M; Bennouna J; Bondarenko I; Douillard JY; Heigener DF; Krzakowski M; Mellemgaard A; Novello S; Orlov S; Summers Y; von Pawel J; Stöhr J; Kaiser R; Reck M
    Target Oncol; 2017 Aug; 12(4):475-485. PubMed ID: 28702806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma.
    Grohé C; Gleiber W; Haas S; Losem C; Mueller-Huesmann H; Schulze M; Franke C; Basara N; Atz J; Kaiser R
    Future Oncol; 2019 Aug; 15(23):2699-2706. PubMed ID: 31282758
    [No Abstract]   [Full Text] [Related]  

  • 13. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.
    Popat S; Mellemgaard A; Reck M; Hastedt C; Griebsch I
    Future Oncol; 2017 Jun; 13(13):1159-1171. PubMed ID: 28326832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
    Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
    Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
    Corral J; Majem M; Rodríguez-Abreu D; Carcereny E; Cortes ÁA; Llorente M; López Picazo JM; García Y; Domine M; López Criado MP
    Clin Transl Oncol; 2019 Sep; 21(9):1270-1279. PubMed ID: 30771085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
    Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
    J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.
    Daga H; Takeda K; Okada H; Miyazaki M; Ueda S; Kaneda H; Okamoto I; Yoh K; Goto K; Konishi K; Sarashina A; Tanaka T; Kaiser R; Nakagawa K
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1225-33. PubMed ID: 26560486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients.
    Ellis PM; Kaiser R; Zhao Y; Stopfer P; Gyorffy S; Hanna N
    Clin Cancer Res; 2010 May; 16(10):2881-9. PubMed ID: 20460487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.